Mizuho Securities cut the price target to $8 from $17, BTIG to $6 from $10, and Wedbush to $7 from $9.
Magenta on Thursday said it will decrease its workforce by 14% and trim other costs as it works to develop its MGTA-117 drug candidate as a potential treatment for acute myeloid leukemia and myelodysplasia.
Price: 2.03, Change: -0.21, Percent Change: -9.60
|-- Earnings Flash (AQS) AEQUUS PHARMACEUTICALS Repor...|
|Insider Buy: Bitnile Holdings|
|Insider Buy: Macerich|
|Insider Sell: Velodyne Lidar|
|Insider Sell: Xometry|